Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A lower-face contouring: one-point versus three-point injection techniques
TCTR20251016020Phase 1Active, not recruiting
- Sponsor
- Mahidol University
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of botulinum toxin type A in masseter hypertrophy (2 arms), sponsored by Mahidol University. Primary endpoint: Lower facial volume change at 6 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
masseter hypertrophy
Beyond the preview
Go deeper on TCTR20251016020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251016020.